Table 2. 20 top KEGG pathways with high representation of the DEGs in E120 vs. E60 and NB vs. E60.
| Pathways_level3 | All_profiles (1142) | profile0 (213) | profile1 (318) | profile6 (482) | profile7 (89) |
|---|---|---|---|---|---|
| Metabolic pathways | 141(12.35%) | 23(10.80%) | 26(8.18%) | 68(14.11%) | 20(22.47%) |
| Pathways in cancer | 64(5.60%) | 16(7.51%) | 18(5.66%) | 23(4.77%) | 5(5.62%) |
| Focal adhesion | 37(3.24%) | 9(4.23%) | 14(4.40%) | 11(2.28%) | 1(1.12%) |
| Regulation of actin cytoskeleton | 37(3.24%) | 5(2.35%) | 13(4.09%) | 17(3.53%) | 2(2.25%) |
| Cell adhesion molecules (CAMs) | 35(3.06%) | 8(3.76%) | 10(3.14%) | 11(2.28%) | 5(5.62%) |
| Axon guidance | 34(2.98%) | 8(3.76%) | 11(3.46%) | 14(2.90%) | 1(1.12%) |
| Endocytosis | 33(2.89%) | 7(3.29%) | 9(2.83%) | 14(2.90%) | 0(0.00%) |
| MAPK signaling pathway | 33(2.89%) | 10(4.69%) | 6(1.89%) | 15(3.11%) | 2(2.25%) |
| Pathogenic Escherichia coli infection | 32(2.80%) | 1(0.47%) | 5(1.57%) | 21(4.36%) | 5(5.62%) |
| Calcium signaling pathway | 30(2.63%) | 5(2.35%) | 5(1.57%) | 14(2.90%) | 4(4.49%) |
| Tight junction | 30(2.63%) | 1(0.47%) | 7(2.20%) | 20(4.15%) | 2(2.25%) |
| Chemokine signaling pathway | 29(2.54%) | 7(3.29%) | 7(2.20%) | 12(2.49%) | 0(0.00%) |
| Phagosome | 28(2.45%) | 3(1.41%) | 9(2.83%) | 10(2.07%) | 6(6.74%) |
| Leukocyte transendothelial migration | 26(2.28%) | 1(0.47%) | 5(1.57%) | 16(3.32%) | 3(3.37%) |
| Neuroactive ligand-receptor interaction | 25(2.19%) | 1(0.47%) | 7(2.20%) | 11(2.28%) | 4(4.49%) |
| Glutamatergic synapse | 24(2.10%) | 8(3.76%) | 3(0.94%) | 9(1.87%) | 3(3.37%) |
| ECM-receptor interaction | 23(2.01%) | 7(3.29%) | 9(2.83%) | 5(1.04%) | 1(1.12%) |
| Cytokine-cytokine receptor interaction | 23(2.01%) | 5(2.35%) | 5(1.57%) | 8(1.66%) | 2(2.25%) |
| Purine metabolism | 23(2.01%) | 3(1.41%) | 12(3.77%) | 6(1.24%) | 1(1.12%) |
| Amoebiasis | 23(2.01%) | 6(2.82%) | 5(1.57%) | 7(1.45%) | 4(4.49%) |